Last reviewed · How we verify

Ganirelix (GnRH antagonist)

Instituto Valenciano de Infertilidad, IVI VALENCIA · Phase 3 active Small molecule

Ganirelix (GnRH antagonist) is a GnRH antagonist Small molecule drug developed by Instituto Valenciano de Infertilidad, IVI VALENCIA. It is currently in Phase 3 development for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).

Ganirelix blocks gonadotropin-releasing hormone (GnRH) receptors to suppress luteinizing hormone (LH) and prevent premature ovulation during assisted reproductive procedures.

Ganirelix blocks gonadotropin-releasing hormone (GnRH) receptors to suppress luteinizing hormone (LH) and prevent premature ovulation during assisted reproductive procedures. Used for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).

At a glance

Generic nameGanirelix (GnRH antagonist)
SponsorInstituto Valenciano de Infertilidad, IVI VALENCIA
Drug classGnRH antagonist
TargetGnRH receptor
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Fertility
PhasePhase 3

Mechanism of action

Ganirelix is a GnRH antagonist that competitively binds to GnRH receptors on pituitary gonadotroph cells, rapidly suppressing LH secretion without an initial flare effect. This prevents the endogenous LH surge that would trigger ovulation prematurely during controlled ovarian hyperstimulation in fertility treatment cycles. By maintaining suppression of LH, it allows exogenous gonadotropins to control follicle development for optimal egg retrieval timing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ganirelix (GnRH antagonist)

What is Ganirelix (GnRH antagonist)?

Ganirelix (GnRH antagonist) is a GnRH antagonist drug developed by Instituto Valenciano de Infertilidad, IVI VALENCIA, indicated for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).

How does Ganirelix (GnRH antagonist) work?

Ganirelix blocks gonadotropin-releasing hormone (GnRH) receptors to suppress luteinizing hormone (LH) and prevent premature ovulation during assisted reproductive procedures.

What is Ganirelix (GnRH antagonist) used for?

Ganirelix (GnRH antagonist) is indicated for Prevention of premature luteinizing hormone surge in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART).

Who makes Ganirelix (GnRH antagonist)?

Ganirelix (GnRH antagonist) is developed by Instituto Valenciano de Infertilidad, IVI VALENCIA (see full Instituto Valenciano de Infertilidad, IVI VALENCIA pipeline at /company/instituto-valenciano-de-infertilidad-ivi-valencia).

What drug class is Ganirelix (GnRH antagonist) in?

Ganirelix (GnRH antagonist) belongs to the GnRH antagonist class. See all GnRH antagonist drugs at /class/gnrh-antagonist.

What development phase is Ganirelix (GnRH antagonist) in?

Ganirelix (GnRH antagonist) is in Phase 3.

What are the side effects of Ganirelix (GnRH antagonist)?

Common side effects of Ganirelix (GnRH antagonist) include Headache, Injection site reactions, Abdominal pain, Nausea, Ovarian hyperstimulation syndrome (OHSS).

What does Ganirelix (GnRH antagonist) target?

Ganirelix (GnRH antagonist) targets GnRH receptor and is a GnRH antagonist.

Related